Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
MiNK Therapeutics, Inc. develops allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. Its platform leverages native and engineered iNKT cells to target tumors, treat viral ARDS, and prevent graft-versus-host disease. The company focuses on scalable manufacturing, proprietary cell engineering, and strategic collaborations to deliver innovative immunotherapies with broad applicability and potential for rapid clinical impact.
This description was generated via AI from an annual report. Updated about 1 year ago.